ViGenCell Inc.

ViGenCell provides immune cell therapy in South Korea. It develops ViTier, an antigen-specific killer T cell therapy, such as VT-EBV-N for NK/T Lymphoma indications and VT-Tri(1)-A for AML indications. Its portfolio also includes ViMedier, a cord blood-derived myeloid suppressor cell therapy

Including VM-GD for GvHD indications and VM-AD for atopic dermatitis indications, and ViRanger, an off-the-shelf allogenic universal T cell gene therapy comprising VR-CAR and VR-GDT for hepatoma and leukemia indications. Founded in 2013, the company is based in Seoul, South Korea.